Remote Access Solutions for Industrial IoT

Industry 4.0 is more than a buzzword; it’s a solution that can resolve supply chain issues. A secure IIOT (Industrial Internet of Things) framework connected to an IoT (Internet of Things) framework already on a company’s network can improve business outcomes with the right solutions. 

This week on the Lion’s Den, a podcast by Red Lion Controls, Barry Turner, Technical Business Development Manager at Red Lion, and Brian Vorphal, Director of Business Development, North America at MB connect Line, joined host Tyler Kern to introduce a new series dedicated to showing how Red Lion solutions can help solve those industry 4.0 challenges. To kick this series off, Tyler, Barry, and Brian discussed the following: 

  • What makes Red Lion remote access solutions unique to the marketplace? 
  • What challenges do industrial customers face in trying to access remote access data and assets? 
  • How does owning remote access solutions benefit systems integrators and OEMs? 

“Some of the greatest challenges we field in the sales section of it is the misinterpretation of cybersecurity,” Vorphal said. “A company choosing to use remote access, which connects to machines from outside of a building, or factory, to the inside of a factory, relies on a portal-scape, servers, connectivity, VPN tunneling, and this sort of thing.”

Barry Turner is a network engineer with more than ten years of experience with Red Lion Controls. Brian Vorphal has a background in electronics engineering and has been with MB Connect Line since January 2017. 

More Episodes in the Series:

What is Your Layered Security Approach? A Look at Defense in Depth

The Impact of 5G on Factory Automation

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More